Prognostic value of routine blood tests along with clinical risk factors in predicting ischemic stroke in non-valvular atrial fibrillation: a prospective cohort study

Table 1 Baseline characteristics of study participants

	Total population (N = 537)
Age	67.7 ± 7.6
Age ≥ 65 (n, %)	350 (65.2)
Male (n, %)	373 (69.5)
Body mass index	24.7 ± 2.9
Past medical history
Diabetes (n, %)	93 (17.3)
Hypertension (n, %)	341 (63.5)
Hyperlipidemia (n, %)	102 (19.0)
Congestive heart failure (n, %)	31 (5.8)
Stroke (n, %)	0 (0.0)
Vascular disease (n, %)	8 (1.5)
CHA₂DS₂-VASc score	2.00 [1.00;3.00]
0	68 (12.7)
1	112 (20.9)
2	166 (30.9)
3	130 (24.2)
4	51 (9.5)
5	10 (1.9)
Number of significant biomarkers*
0	292 (54.8)
1	198 (37.1)
2	38 (7.1)
3	5 (0.9)
Mean follow-up duration (years)	2.2 ± 0.6
Clinical event during follow-up
Ischemic stroke	10 (1.9)
CHA₂DS₂-VASc score
0^†	0 (0.0)
1^†	1 (0.9)
2^†	4 (2.4)
3^†	4 (3.1)
4^†	1 (2.0)
5^†	0 (0.0)
Other thromboembolic events	0 (0.0)
Major bleeding	10 (1.9)
Hemorrhagic stroke	6 (1.1)
Gastrointestinal bleeding	5 (0.9)
Major cardiac adverse event	7 (1.3)
Myocardial infarction	1 (0.2)
Heart failure at admission	6 (1.1)
Cardiac death	0 (0.0)
Anti-coagulation at baseline (n, %)	382 (71.1)
Warfarin use	160 (29.8)
NOAC use	222 (41.3)

The data are presented as mean ± standard deviation or median [interquartile range] for continuous variables and number (percentage) for categorical variables
NOAC new oral anticoagulant
*The significant biomarkers were RDW ≥ 13.5%, creatinine ≥ 1.11 mg/dL, and PDW ≥ 13.2%. Four patients with no value of PDW were excluded
^†Denominator for this low is the number of patients with each CHA₂DS₂-VASc score

ISSN: 2466-1171